Breast Cancer Survivors

Chemo Secrets From a Breast Cancer Survivor

Undergoing chemotherapy can be one of the most terrifying things that you go through in your life. One of the most frightening things about chemotherapy is the lack of real information that most people have about it, and the unknown makes it so much more frightening as a result. This eBook, written by a young cancer survivor gives you the real story about what chemo is all about. The most valuable information you can get about chemotherapy is from someone that has already experienced it. This PDF eBook allows you to download and read it as soon as your order it. You can begin your journey of reassurance as soon as you want! Because that's what this is about: chemo does not have to be a terrifying unknown! Other people have gone through it before, and want to help you through it as well! This eBook is the guide through chemo that many people wish they could have had, and now you can have it yourself! Read more here...

Chemo Secrets From a Breast Cancer Survivor Overview


4.6 stars out of 11 votes

Contents: Ebook
Author: Nalie Augustin
Price: $19.97

Access Now

My Chemo Secrets From a Breast Cancer Survivor Review

Highly Recommended

Of all books related to the topic, I love reading this e-book because of its well-planned flow of content. Even a beginner like me can easily gain huge amount of knowledge in a short period.

I personally recommend to buy this ebook. The quality is excellent and for this low price and 100% Money back guarantee, you have nothing to lose.

Regional Chemotherapy with Chemoembolization

In contrast to the poor response rates for systemic chemotherapy, a large number of reports have shown promising response rates of 40-68 for a variety of agents which may be administered through the hepatic artery as a bolus injection, often with some agent such as lipiodol, microspheres, or starch which allows for arteriolar embolization. These agents include doxorubicin, cisplatin, mitomycin C, and neocarzinostatin.4 Side effects include fever (95 ), abdominal pain (60 ), anorexia (20 ), and ascites (20 ).

SST Analogs in the Treatment of Nonendocrine Cancers Possible Application of New Analogs and Receptor Targeted

The first report showing antiproliferative activity of SST was published in 1978 by the editor of this book and revealed that SST inhibited the proliferation of normal pituitary cells (the mitogenic action of TRH on the anterior pituitary gland in vitro).11 A few years later, Mascardo and Sherline,12 showed that SST inhibited the centrosomal separation and cell proliferation of some tumor cells (HeLa and gerbil fibroma cells). As a consequence of these two findings an enormous number of data have been published concerning anti-growth effect of SST and its analogs on normal and tumoral tissues. At the end of 1980s, the list of neoplasms whose growth processes were changed via SST analogs was very long and included besides various endocrine tumors, which is the subject of another chapter in this book, also several nonendocrine tumors such as pancreatic cancer, breast cancer, prostatic cancer, colon cancer, hepatocellular cancer, renal cancer, laryngeal cancer, meningioma, lymphoma,...

CSF1 in Breast Cancer

The mechanism by which mammary epithelial cells undergo genetic changes that result in acquisition of the ability to invade and colonize distant sites is complex (2,41,42). Normal and malignant mammary epithelium and the surrounding stromal cells produce and respond to various growth factors. Among the stromal cells, macrophages play a unique role because they are recruited into mammary gland carcinomas (43,44). The fact that in the absence of such tumor-associated macrophages, metastatic progression of mammary gland tumors is profoundly reduced (17) as well as the fact that CSF-1 blockade suppresses tumor growth, MMP production, and macrophage recruitment in embryonic tumors and colon cancer (40) support the paradigm that CSF-1 enhances progression of malignancies through effects on the recruitment and control of macrophages that regulate tumor cell growth, angiogenesis, and the ECM. The recent discovery of highly specific, small-interfering (siRNA) molecules as promising candidate...

Treatment Induced Leydig Cell Failure from Chemotherapy

Leydig cells are much less vulnerable to damage from cancer therapy than germ cells. This is likely due to their slow rate of turnover 73 . For example, chemotherapy-induced Leydig cell failure resulting in androgen insufficiency and requiring testosterone replacement therapy is rare. However, studies suggest that Leydig cell dysfunction may be observed following treatment with alkylator-based regiments. In fact, raised plasma concentrations of LH, combined with low levels of testosterone, are the hallmarks of Leydig cell dysfunction. When Leydig cell dysfunction occurs prior to or during puberty, affected individuals will experience delayed and or arrested pubertal maturation and the failure to develop secondary sexual characteristics 76 . If the insult follows completion of normal pubertal development, observed symptoms include loss of libido,erectile dysfunction, decreased bone density and decreased muscle mass 76 . Measurements of testosterone and gonado-tropin concentrations are,...

Cytotoxic Effects of Chemotherapy

Testicular dysfunction is among the most common long-term side effects of chemotherapy in men. The germinal epithelium is particularly susceptible to injury by cytotoxic drugs secondary to a high mitot-ic rate. In 1948, azoospermia after an alkylating agent (nitrogen mustard) was described in 27 of 30 men treated for lymphoma 81 . Subsequently, it became apparent that all alkylating agents are gonadotoxic 31, 49, 59 , while antimetabolite therapy (with, e.g. methotrexate or mercaptopurine) does not have a long-term impact on male fertility. Cisplatin-based regimens, including vinblastine, bleomycin and etoposide, result in temporary impairment of sper-matogenesis in all patients, but a significant percentage recovers 27 . The agents most commonly gonadotoxic in males are listed in Table 14.3. Initial reports,based upon histological studies and normal basal FSH levels from small numbers of patients, suggested that the immature testis was relatively resistant to chemotherapy 75 . More...

Chemotherapy and Biologic Agents

No combination chemotherapy has been proven more advantageous than to DTIC alone. DTIC has a 20 response rate but, as with other chemotherapeutic regimens, this has not been durable. One combination known as the Dartmouth Regimen or CBDT (carmustine (BCNU), cisplatin, DTIC, and tamoxifen) had some initial favorable results and is favored by many oncologists. Phase II and Phase III studies are ongoing to determine if there is an advantage of CBDT to DTIC alone.

Effects of Chemotherapy

Cyclophosphamide, either alone or in combination with other agents, is known to damage the germinal epithelium. In a meta-analysis of 30 studies that examined gonadal function following various chemotherapy regimens, gonadal dysfunction correlated with the total cumulative dose of cyclophosphamide more than 300 mg kg was associated with > 80 risk of gonadal dysfunction 66 . A study of men treated for pediatric solid tumors reported permanent azoospermia in 90 of men treated with cyclophosphamide doses > 7.5 g m2 84 . Other studies have also found that 7.5-9 g m2 of cyclophosphamide is associated with a significant risk of testicular injury 5,39 . Hodgkin's disease (HD) patients treated with six or more courses of mechlorethamine, vincristine, procarbazine and prednisone (MOPP) have also demonstrated permanent azoospermia attributable to both of the alkylating agents, mechlorethamine and procarbazine. Procarbazine appears to play a major role in this process. Hassel et al. studied...

Palliative Therapy Chemotherapy

Khan 9 , in the consensus document of guidelines for the diagnosis and treatment of cholangiocarcinoma, reported to date, a review of over 65 disparate studies using chemotherapy and or radiations suggests that was no strong evidence of survival benefit. However, most studies were small, lacked control groups (phase II) and were difficult to interpret. Recently, a German group tested a dose of intra-arterial gemcitabine > 1000 mg m2 for patients with unresectable ICC who did not respond to systemic chemotherapy. The drug was administered with and without starch microspheres into the hepatic artery 20 , with good tolerance and respectable results. therapy are case reports on unresectable cholangiocarcinoma 23 or with distant metastases 22 . Other immunotherapeutic agents are a monoclonal antibody against vascular endothelial growth factor receptor (bevacizumab) and tyrosine kinase inhibitors, either alone or in combination with chemotherapeutic agents 18 . The potential benefit of...

Concurrent Chemotherapy

Assuming that the biological characteristics of squamous cell carcinoma of the trachea and carina and their response to radiation and chemotherapy are very similar to those of primary carcinoma of the bronchus and lung, it is recommended that radiation therapy be combined with chemotherapy for patients with unresectable or gross residual squamous cell carcinoma. Dillman and colleagues compared radiation therapy alone (60 Gy 30 fractions 6 weeks) with sequential chemoradiotherapy, in which two cycles of induction chemotherapy (cisplatin 100 mg m2 IV on days 1 and 29, and vinblastine 5 mg m2 IV on days 1, 8, 15, 22, and 29 ) were administered first, and radiation therapy (60 Gy 30 fractions 6 weeks) was administered subsequently starting on day 50.34 The 5-year survival rates were 7 with radiation therapy alone as compared to 16 with chemoradiotherapy. Arriagada and colleagues also compared radiation therapy alone with chemoradiotherapy, in which 3-monthly cycles of VCPC (vindesine 1.5...

Example 153 Metaanalysis of adjuvant chemotherapy for resected colon cancer in elderly patients

Figure 15.1 Hazard ratios and 95 per cent confidence intervals for death from any cause (panel (a)) and recurrence (panel (b)) by treatment group (Sargent DJ, Goldberg RM, Jacobson SD, MacDonald JS et al., 'A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients', New England Journal of Medicine, 345, 1091-1097. (2001) Massachusetts Medical Society.)

Regional Chemotherapy

The hepatic artery is the dominant source of blood supply for macroscopic tumor deposits. The liver during the first pass extracts chemotherapeutic drugs that are ideally suited for regional infusion. Floxuridine (5-FUDR) is almost completely extracted (94-99 ) during the first pass through the liver. There are seven randomized trials which showed a significantly higher response rate for intrahepatic infusion (48-62 ) compared to systemic chemotherapy (0-38 ). Two prospective randomized trials (National Cancer Institute study and Memorial Sloan Kettering study) have shown a modest median survival benefit only in patients without evidence of portal node metastases or other sites of extrahepatic disease. Most of the studies were compromised by small numbers, patients who never got a particular treatment, and patients who were allowed to crossover from the systemic arm to the intrahepatic arm. There has been no study which demonstrated a benefit in patients with nodal or other...

Adjuvant Systemic Chemotherapy

Following liver resection or ablation, there is no single agent or combination of agents which have demonstrated a survival benefit in an adjuvant setting. In spite of this, many patients who have not previously received 5-FU chemotherapy will be offered this regimen. Folinic acid (5-FU) is an antimetabolite which works by preventing DNA methylation of tumor cells. Patients who have already received 5-FU may be offered Camptosar (CPT 11) or a continuous infusion of 5-FU. Ideally, these patients should be studied in a prospective clinical trial.

Chemotherapy and Secondary Leukemia

For more than two decades, secondary leukemia has been linked to alkylating agent therapy 13 . The risk of developing secondary leukemia following treatment with alkylating agents appears to be dose and agent-dependent. MOPP chemotherapy (mechlor-ethamine, vincristine, prednisone and procarbazine) has resulted in cumulative frequencies of secondary leukemia ranging from 3-5 at 7 years, and reaching

Chemotherapy Clinical Manifestations

As increasing numbers of patients are cured with chemotherapy, reports of agents responsible for acute, and possibly chronic, pulmonary toxicity are expanding. Drug-related lung injury is most commonly an acute phenomenon, occurring during or shortly after the chemotherapeutic agent(s) are administered 25 . Three typical patterns of pulmonary toxicity have been described pneumonitis or fibro-sis, acute hypersensitivity (or inflammatory interstitial pneumonitis) and noncardiogenic pulmonary edema. Hypersensitivity reactions are rare but can be induced by such agents as methotrexate, procar-bazine, bleomycin, BCNU and paclitaxel. Cough, dyspnea, low-grade fevers, eosinophilia, crackles on exam and interstitial or alveolar infiltrates are noted. These reactions occur during therapy and usually resolve with discontinuation of the offending drug and, potentially, corticosteroid use. Noncardiogenic pulmonary edema, characterized by endothelial inflammation and vascular leak, may arise upon...

Case study Cathepsin D and diseasefree survival in nodenegative breast cancer

Ferrandina et al.33 described a meta-analysis of 11 studies which examined the relation between cathepsin D (a proteolytic enzyme) and disease-free survival (time to relapse) in node-negative breast cancer. Their inclusion criteria included the presentation of outcome separately for groups with high and low cathepsin D values. Studies were included if they had used a cytosol assay with a cutpoint in the range 20-78 pmol mg or a semiquantitative method based on histochemical assay. It is not clear why this range was chosen. It seems that no studies were excluded because they treated cathepsin D values as a continuous variable. Some studies were excluded because they did not present results separately for patients with node-negative breast cancer and others because they reported overall survival rather than disease-free survival. These exclusions are carefully documented in an appendix. The authors apparently did not evaluate methodological quality and included all studies that had...

Neoadjuvant Chemotherapy

A number of regimens have evolved in an effort to reduce treatment-related morbidity. Most current regimens are variations of combination chemotherapy regimens consisting of cis-platinum, 5-fluorouracil, and other agents used in conjunction with radiation therapy designed to take advantage of the radio-sensitizing properties of cis-DDP and 5-FU. A typical regimen involves 3 cycles of cis-DDP and 5-FU, with radiation therapy timed to begin at the initiation of chemotherapy and continued to a total dose of 4000-4500 cGy. The surgery is timed to allow complete recovery from the neutropenia of chemotherapy, which is usually 3-6 weeks after the last chemotherapy cycle. Although it is assumed that delays beyond 8 weeks will lead to technical difficulties with the surgery, the onset of fibrosis is variable and longer delays due to morbidity of the neoadjuvant treatment occasionally require that surgery be postponed beyond the 6-week ideal. The effectiveness of treatment can be assessed in...

Cytotoxic Chemotherapy

In 1994 the World Health Organization (WHO) stated that just 24 drugs could be considered essential for the rational management of malignant disease. Despite this, the British National Formulary 52 lists over 50 cytotoxic agents available for prescription in the United Kingdom. There is little doubt that some of these represent major advances in the fight against cancer but for others the risk benefit ratio is less clear. Such controversies are not new and arguments have raged over the years concerning the place of chemotherapy in the treatment of neoplastic disease (Bailar and Gornik, 1997 Cunningham, 1995 Kramer and Klausner, 1997 Mead, 1995). In recent times this difficult area has become further complicated by the development of pharmacoeconomics as a science and the growing importance of cost-effectiveness when deciding where resources are best used (Grusenmeyer and Wong, 2007). It is becoming increasingly important to be able to target treatment to those who will benefit most....

Alcohol and Breast Cancer

Although many studies have shown that breast cancer rates are higher among heavier drinkers, a number of research reports suggest that only a small increase in risk begins to appear among women who normally consume just one or two drinks per day. This is not found consistently in all studies. At our institute at Boston University, we have completed a study of wine, beer, and spirits as they relate to breast cancer by using data from the Framingham Study that has been

Chemotherapy for Patients with Advanced STS

Another regime with activity in patients with metastatic STS is MAID, a combination of mesna, doxorubicin, ifosfamide, and dacarbazine. Response rates in approximately half of all patients treated have been reported using this combination. Ongoing clinical trials comparing single agent and combination chemotherapies will further define the appropriate therapy for patients with stage IV disease.

Regional Chemotherapy for Patients with Extremity STS

Regional chemotherapy is a therapeutic option for patients with advanced STS of the extremity, particularly when amputation is the only alternative. Regional chemotherapy is delivered by surgically isolating the vasculature at the root of the limb and applying a tourniquet proximally. A cardiopulmonary type pump oxygenator is used to maintain circulation and oxygenation of the limb through the cannulated vasculature at the root of the extremity. This procedure is called isolated limb perfusion (ILP). A hyperthermic, hyperoxic perfusion is then commenced which delivers high dose chemotherapy to the extremity only. The limb is perfused for approximately one hour. At completion, the extremity is flushed, the tourniquet is released, the catheters are removed, and the vessels are repaired.

Adjuvant or Neoadjuvant Chemotherapy for Patients with STS

Single institution and national trials of adjuvant chemotherapy have failed to demonstrate an overall survival benefit for patients treated with adjuvant chemotherapy following resection of STS, although several prospective randomized studies suggest that it may prolong disease free survival. A recent meta-analysis suggests that adjuvant chemotherapy provides a minimal benefit in terms of disease free survival in patients with localized completed resected STS but no improvement in overall survival.16 The use of adjuvant chemotherapy remains an area of significant controversy, and its use should be restricted, whenever possible, to patients participating in prospective clinical trials. Patients at particularly high risk for death from their disease should be entered into investigational trials of neoadjuvant (preoperative) or adjuvant chemotherapy. These include patients with large (> 8 cm), high grade extremity, retroperitoneal or visceral tumors. As a rule, these patients have a...

MMR Apoptosis and Chemotherapy Resistance

The role of MMR in apoptosis signalling may have relevance for chemotherapy with DNA-damaging agents, because drug resistance may develop by loss of MMR function in a single selection step (Aebi et al., 1996). Loss of MMR may also confer resistance to low doses of ionizing radiation (Fritzell et al., 1997 DeWeese et al., 1998) (see review by Li (1999)).

Breast Cancer During Pregnancy

Fortunately this occurs in less than 5 of breast cancer patients. It usually presents as a breast mass, and delays in diagnosis are common. This is due to the considerable enlargement of the breast associated with pregnancy precluding effective clinical breast examination. Mammography is generally not utilized during pregnancy because the proliferative changes in the breast result in a white out of the mammogram. Although surgical biopsy or US guided core biopsy are generally well tolerated in pregnant women, delays in performing biopsy are common. US is usually performed in place of mammography for diagnostic purposes. Because of the inability to shield the fetus from radiation, breast conserving therapy must be carefully considered. There has not been any documented advantage to aborting the fetus. Although it has been thought that breast cancer presenting during pregnancy carries a worse prognosis, the decreased survival rate is probably attributable to the later stage of...

Breast Cancer in the Male Breast

Male breast cancer is unusual, and accounts for about 0.5 of all breast cancer. Risk factors are similar to those for women. The prognosis is similarly related to the stage of presentation. Male breast cancer usually presents as a subcutaneous mass beneath the nipple-areola complex. It usually presents in men between the ages of 60-70 approximately 10 years older than the mean age of presentation of women. The only pathological entity not seen in the male breast is lobular carcinoma in situ, and infiltrating lobular carcinoma is rare. Treatment is total mastectomy and axillary lymphadenectomy. Since randomized trials of adjuvant therapy have not been performed with male breast cancer patients, decisions for systemic adjuvant therapy are guided by the same factors as are used in female breast cancers.

Intrathecal Chemotherapy

Chemotherapy exposures are associated with neu-robehavioral consequences, although the effects may not be as devastating as those produced by CRT. Chemotherapeutic agents for the treatment of childhood ALL administered by the intrathecal route include methotrexate, cytarabine, and hydrocortisone, often in combination. Acute toxicity as a result of in-trathecal methotrexate and intrathecal cytarabine can include chemical arachnoiditis, hallucinations, somnolence, seizures, and neurological symptoms 39,40 . Several months to years after termination of intrathecal methotrexate therapy, patients may exhibit radiographic evidence of cortical atrophy, necrotizing leukoencephalopathy, subacute myeloen-cephalopathy, mineralizing angiopathy, and cerebel-lar sclerosis 29,41 . Raymond-Speden et al. compared ALL patients with chronic asthmatics. This study demonstrated that the detrimental effects of intrathecal chemotherapy are independent of the limitations of having a chronic disease (i.e.,...

Invasive Breast Cancer

Infiltrating ductal carcinoma is the most common form of invasive breast cancer and accounts for about 75 of all invasive breast cancers. It arises from ductal cells lining milk ducts. Histologic subtypes which have a more favorable prognosis include tubular, colloid or mucinous, and medullary carcinoma. Patients must be evaluated for the ability to withstand the stress of the proposed surgical procedure. Most patients tolerate surgery for breast cancer since a body cavity is not entered and critical organs are not manipulated. Very frail patients and those of advanced age must have their therapy customized to that which they can acceptably tolerate.

And Chemotherapy on Reproductive Outcomes

With more childhood cancer survivors retaining fertility, pregnancy outcome data is now available. Of 4,029 pregnancies occurring among 1,915 women followed in the Childhood Cancer Survivor Study (CCSS), there were 63 live births, 1 stillbirths, 15 miscarriages, 17 abortions and 3 unknown or in gestation. Risk of miscarriage was 3.6-fold higher in women treated with craniospinal radiotherapy and 1.7-fold higher in those treated with pelvic radiotherapy. Chemotherapy exposure alone did not increase the risk of miscarriage. Compared with siblings, however, survivors were less likely to have live births and more likely to have medical abortions and low birth-weight babies 35 .

Effects of Chemotherapy on Ovarian Function

The dose-response relationship of alkylating agents, and the effect of age, is a recurring theme in studies of fertility following chemotherapy. Amenorrhea and ovarian failure occur more commonly in adult women treated with cyclophosphamide and other alkylating agents than with adolescents, with pre-pubertal females tolerating cumulative cyclophos-phamide doses as high as 25 gm m2 11,23 .In examining protocols with common chemotherapy, 86 of women > 24-30 years have been shown to have ovarian failure, compared with 28-31 of younger women 2,23 . It is clear that the sterilizing effects of all alkylating agents are not equal. Mechlorethamine and procar-bazine together are perhaps the most damaging of the alkylating agents. Newer risk-adapted protocols in pediatric oncology have been developed to avoid mechlorethamine or procarbazine and to limit cumulative doses of alkylating agents, without negatively impacting the efficacy of the chemotherapy regimens. This is best illustrated by...


The role of adjuvant chemotherapy alone after resection for hilar cholangiocarcinoma is still unclear and, according to some authors, it is indicated in resected patients with positive lymph nodes 3 . The most commonly used drug is 5-FU, alone or in combination with others such as methotrexate, leucovorin, cisplatin, mitomycin C or IFN-a. Injection routes aside from the systemic are loco-regional, intra-arterial and intraductal. However, most of the studies report small series, retrospective single group experiences with data that are not comparable. A recent controlled randomized phase-III study by Takada 4 reports data on adjuvant treatment after resection of bilio-pancreatic tumours in 158 pancreatic cancers, 118 extrahepatic biliary tract neoplasms, 112 gallbladder cancers, and 48 carcinomas of the papilla of Vater. Comparison between a group of patients who underwent adjuvant chemotherapy with two cycles of mitomycin C plus 5-FU, followed by oral long-term uptake of 5-FU until...

Breast Cancer

Radiation to the breast tissue may induce secondary breast cancers. Although the risk is not isolated to those with HD, SMNs are recognized as a leading cause of death in long-term survivors of HD, with breast cancer representing the most frequent solid tumor among such women 4, 57,60 . Radiation exposure to the breast between the ages of 10-30 years imparts the greatest risk of developing secondary breast cancer. During puberty, the breast undergoes rapid growth and differentiation secondary to a surge in pituitary hormones and the resultant increase in estrogen. Hormonal stimulation of proliferating tissue may potentiate the risk of developing subsequent breast cancer. The role of genetic predisposition is less clear. It has been speculated that genetic predisposition could accelerate the tumorigenic process by providing the initiating event, as is known to occur for renal cancer in rats that carry the tuberous sclerosis 2 gene 22 . Breast cancer was the most frequent SMN in the...

Breast Cancer Data

An increase in breast cancer incidence in recent years has resulted in a substantial portion of health care dollars being directed towards research in this area. The aims of such research include early detection through mass screening and recurrence prevention through effective treatments. The focus of this investigation was to determine which prognostic measures were predictive of breast cancer recurrence in female patients. 6-time until breast cancer recurrence in months (data set variable time) Table 7.5 Breast Cancer Data

What is the usefulness of tumour markers in disease management

The decision to test for tumour markers can depend ultimately on a clinician's management for a patient. To provide patient care, several guidelines have now been produced by a number of expert panels. Examples include guidelines by the ASCO. It recommends that only oestrogen receptor and progesterone receptor values are of benefit in predicting which breast cancer patients are suitable for endocrine therapy (ASCO, 1996, 1998 Hammond and Taube, 2002). The College of American Pathologists (CAP) has evaluated tumour markers, in both 1994 and 1999, and has identified those that it recommends for clinical use for breast, prostate and colon cancer (Henson et al., 1995 Hammond et al., 2000 Hammond and Taube, 2002).

Useful markers for disease management

As a result of low sensitivity and low specificity of CA15-3, or BR27.29, it is not recommended that these MUC-1 tumour markers are used for screening, diagnosis or staging of breast cancer. However, they can be useful in determining metastatic disease (Molina et al., 1999 Bast et al., 2001).

Transforming Growth Factora

A variety of solid tumors, including gliomas, and kidney and lung tumors, were shown to secrete TGF-a. (Nickell, Halper, & Moses, 1983) The correlation between enhanced TGF-a activity, cellular proliferation, and neoplastic transformation has been documented in a number of studies in transgenic mice (Jhappan et al., 1990 Sandgren, Luetteke, Palmiter, Brinster, & Lee, 1990 Smith, Sharp, Kordon, Jhappan, & Merlino, 1995). Smith et al. demonstrated that enhanced TGF-a expression conferred a growth advantage in hyperplastic tissue and tumors, and that the tumorigenic ability of TGF-a arises from its stimulation of epithelial cell proliferation and its effects on prolonged cell survival. For example, TGF-a overexpression in transgenic mice resulted in mammary gland alveoli and terminal duct hyperplasia (Matsui, Halter, Holt, Hogan, & Coffey, 1990). Morphologic abnormalities in the mammary tissue included lobular hyperplasia, cystic hyperplasia, adenoma, and adenocarcinoma. Like...

Molecular Monitoring Of Human Cancers In Blood And Prognostic Implications

Molecular analysis of aberrant p15 methylation in blood may possibly enable disease monitoring and risk assessment.12 p15 methylation may play a role in cancer progression in addition to leukemogenesis52 and aberrant p15 methylation appears to have important prognostic implications. The median survival time of patients with acute leukemia with p15 methylation at diagnosis was notably reduced as compared with those carrying unmethylated p15 alleles.12 This molecular approach may be applied to many other tumor suppressor genes, DNA repair genes, or metastasis suppressor genes, which are methylated in different tumor types. For example, DAPK hypermethylation has been associated with shortened survival in patients with lung cancer.18 RASSF1A and APC hypermethylation in blood of patients with breast cancer has also been associated with reduced survival.53 Moreover, the MSP analysis of plasma samples may potentially be applied for risk assessment and early detection of human cancers. p15...

Methylation Profiling Of Tumor Cells And Tumor Dna In Other Body Fluids From Patients With Cancer

Breast cancer ples from patients with a variety of cancers (Table 14.2).2 Epigenetic alterations occur early in primary neoplasia, and promoter hypermethylation is an early phenomenon in premalignant or morphologically benign lesions. Many research groups have analyzed epigenetic markers in body fluids of patients with cancer as compared with healthy individuals. Tumor-associated methylated DNA was detected in exfoliated tumor cells isolated from body fluids (Table 14.2).62 Thus far, DNA hyperm-ethylation has been found in body fluids from patients with different cancer types, including lung cancer, liver cancer, breast cancer, prostate cancer, head and neck cancer, colon cancer, and acute leukemia.12'29-31'34'55'6364 As opposed to conventional immunocytological detection, molecular detection in body fluids offers higher sensitivity. Prostate specific antigen (PSA) has been applied as a protein tumor marker for the diagnosis of prostate cancer with low specificity. Compared to protein...

Methylation Profiling Of Circulating Tumor Dna In Plasma And Serum From Patients With Cancer

Elevated levels of circulating nucleic acids have been shown in patients with cancer.36 DNA concentrations in plasma and serum are especially low in healthy individuals (2 to 30 ng ml) as compared to those in patients with cancer (20 to 1200 ng ml), attributable to the presence of circulating tumor DNA.36-38 In plasma of patients with breast cancer, angiosarcoma, melanoma, or head and neck cancer, the fractional concentration of tumor DNA was determined to range from 3 to 93 (mean 53 ) of the total amount of circulating DNA.38 Tumor DNA may possibly be enriched in plasma by selective DNA release from tumor cells or inhibition of tumor DNA degradation as protected from DNase digestion. MGMT, RAR 2, and or RASSF1A hypermethylation was demonstrated in circulating DNA isolated from preoperative plasma of patients with cutaneous melanoma.21 In serum, the DNA concentration is also much higher among patients with cancer as compared to that among healthy individuals.39 Elevated DNA levels...

Trks And The Regulation Of Cancer Growth

The regulation of cell number during development or in cancer growth reflects a balance of signals that promote proliferation or differentiation and survival or apoptosis. Neurotrophin activation of Trks helps to determine this balance during development and oncogenesis. Thus in cancer Trks can be helpful or hurtful biological modifiers and positive or negative prognostic indicators. Trk activities have been described in diverse cancers arising from many tissues including medullary thyroid carcinoma (McGregor et al., 1999), Wilms' tumor (Donovan et al., 1994 Eggert et al., 2001), glioblastoma multiforme (Singer et al., 1999), lung cancer (Ricci et al., 2001), pancreatic cancer (Schneider et al., 2001), melanoma (Innominato et al., 2001), leukemia (Eguchi et al., 1999), breast cancer (Descamps et al., 1998) and Ewing's sarcoma (Nogueira et al., 1997) (Table 1). A review of well described Trk activities in prostate cancer, medulloblastoma and neuroblastoma serves to demonstrate the...

Evaluation of Cell Morphology

The number of epithelial and foam cells and ratio of epithelial to foam cells have been assessed in different breast cancer risk populations (King et al., 1984 Papanicolaou et al., 1958 Sauter et al., 1997). It was found that as breast cancer risk increased, the number of epithelial cells, as well as the ratio of epithelial to foam cells, increased. Increased breast density suggests more proliferative activity. Increased breast density as seen on mammography has been linked to increased breast cancer risk (Wolfe, 1976). Among a population of women in whom NAF cytology was collected, those with the greatest mammographic density were found to have a fourfold increased risk of atypical hyperplasia (Lee et al., 1992a). Longitudinal studies have demonstrated the usefulness of abnormal NAF cytology in predicting future breast cancer risk. A prospective study which enrolled 2071 Caucasian women found that, after an average of 12.7 years of follow-up, the relative risk (RR) for women who...

Herceptin trastuzumab

Herceptin was the first therapeutic monoclonal antibody that was approved by the US FDA for the treatment of solid tumours in 1998 (Bell, 2002 Freebairn et al., 2001). Unlike Rituxan, Herceptin is a humanized antibody, which is directed against the external domain of the human epidermal growth factor receptor-2 (HER-2). It has been approved for the treatment of patients with metastatic breast cancer whose tumours overexpress HER-2 receptors. HER-2 is a non-mutated, tumour-associated, cell surface antigen and a member of the type I growth factor receptor family (Rubin and Yarden, 2001). Overexpression of HER-2 has been shown in 20-30 of patients with breast cancer and in a number of other epithelial tumours (Walker, 2000). In addition, high levels of expression of HER-2 have often been associated with more aggressive disease, poor response to the conventional form of therapy, increased risk of metastasis and poor survival in patients with breast cancer (Cook et al., 2001). As HER-2...

Biochemical Events in Target Tissues Subsequently Detected in Surrogate Tissues

These markers involve analytes that are formed and secreted, or lost, by the primary tissue of interest through a physiological, pathophysiological, toxicological, or pharmacological process. The chapter by Petricoin et al. (Chapter 7) demonstrates how a portion of the low-molecular-weight circulatory proteome may consist of aberrantly processed protein fragments produced in the tumor microenvironment and intimates that a suitably sensitive method may have diagnostic implications for early cancer detection and monitoring disease progression. Similar applications can be found for these types of biomarkers in other chapters. The chapter by Wong (Chapter 14) demonstrates how methylation profiling can examine methylation patterns of DNA lost from a primary tumor and detected in the circulation, while the chapter by Ghossein et al. (Chapter 13) demonstrates a series of examples how sensitive RT-PCR methodologies can be used to detect circulating tumor cells in blood. Sauter (Chapter 9)...

Quasiexperiments casecontrol studies and cohort studies

A case-control study may be used to investigate a problem related to a cause of disease. Patients with a particular condition (cases) are compared with an identical group of individuals who do not have the condition (controls). Both groups should be identically matched except for the condition under study. Case-control studies are generally retrospective, and accounts of past history and exposure are investigated to ascertain the common lifetime exposures, linking these to possible causation of disease. The benefits of this form of research are that the researcher can study multiple exposures and diseases that have long latent periods, e.g. breast cancer may recur some 15-20 years later, hence the benefits of breast screening should be evaluated over this time. It is also useful in situations where it would be unethical to carry out an experimental study and where little is known about the cause of the disease. The evidence gained from this sort of research generally is considered...

Randomized controlled trials

To compare nurse-led versus doctor-led follow-up after a diagnosis of breast cancer and completion of treatment. After a diagnosis of breast cancer, patients are generally followed up by their consultant or registrar for a period of 5-10 years. This randomized study compared follow-up by two specially trained

Where did it all begin

This challenge was taken up and in 1995 scientists had developed a potent specific inhibitor of Bcr-Abl. Preclinical work was encouraging and in the laboratory the inhibitor (now known as imatinib) did not demonstrate significant activity against normal cells, in stark contrast to traditional chemotherapy treatment. Clinical trials began and, in 1998, 31 patients were entered into a trial using imatinib. All 31 had a complete haematological response to treatment and one-third had a cytogenetic response, i.e. elimination of the Philadelphia chromosome. After these exceptional results phase 2 trials were initiated and produced the same exciting results. In addition, imatinib was well tolerated and had very few side effects. Again the improved patient outcomes were a direct result of the collaboration of laboratory scientists and clinical staff, not forgetting the pioneering and brave patients.

Future considerations

Since the discovery of hybridoma technology, mAbs have been generated against a wide range of human tumour antigens. These antibodies were subsequently used to unravel the importance of such antigens in the biology of cancer, as diagnostic agents, and more recently in cancer treatment. Unfortunately, the first generation of mAbs that were generated in mice were immunogenic in cancer patients. This in turn prevented repeated administration of such antibodies, limiting their efficacy. After advances in genetic engineering, it has become possible to develop the recombinant form of mice monoclonal antibodies (i.e. chimeric or humanized). Three such unconjugated antibodies are currently being used in the management of cancer patients, because such antibodies prolong survival. More importantly, patients treated with mAbs do not develop high-grade side effects which are often associated with the use of conventional chemotherapy. In other cases, the anti-tumour activity of mAbs has been...

Radiolabelled mAbs as radioimmunoconjugate agents

Zevalin (90Y-labelled anti-CD20 antibody) to unconjugated anti-CD20 antibody (Rituxan) in the treatment of patients with NHL, 143 NHL patients were randomized into two groups, in a phase 3 clinical trial. The overall response rate in patients treated with Zevalin and Rituxan was 80 and 56 respectively. As explained above, the advantage of RIT over unconjugated mAb is that the former penetrates deeper into the tumour mass and can also kill antigen-negative tumours in a crossfire effect. Therefore, patients who are not responsive to, or relapse after chemotherapy or treatment with unconju-gated antibodies, may be suitable candidates for RIT approaches (Dillman, 2002 Foran, 2002 Juweid, 2002).

Highthroughput Methods For Methylation Profiling In Cancer Cells And The Selection Of Target Genes As Epigenetic

MSO is suitable for examining a panel of genes among clinical samples.81 This approach can generate a robust data set for discovering methylation profiles in cancer cells. Candidate epigenetic markers with diagnostic and prognostic implications can be identified. For example, after the profiling of methylation alterations of CpG islands in ovarian tumors, the duration of progression-free survival after chemotherapy was found to be significantly shorter for patients with Stage III IV ovarian carcinoma with higher levels of concurrent methylation as compared with those possessing lower methylation levels.82 A higher degree of CpG island methylation is associated with early tumor recurrence after chemotherapy. A selected group of

Rituxan antibody rituximab

Rituxan is jointly marketed by two American companies (IDEC Pharmaceutical and Genentech, California) for short-course outpatient treatment of relapsed or refractory CD20-positive, low-grade or follicular B-cell NHL. Rituxan is a less toxic alternative to chemotherapy and can induce anti-cancer activity by binding to CD20-positive cells, inducing apoptosis, recruiting immune effector functions (i.e. mediating ADCC) and activating complement (Scott, 1998 Hainsworth, 2000). As a single agent, rituximab has been shown to produce a response rate of 50 in patients with relapsed low-grade and follicular NHL. When added to standard chemotherapy in patients with diffuse, large, B-cell NHL, it has also been able to prolong survival in such patients (Dearden, 2002). Treatment-related toxicity, which occurs most often with the first infusion of the antibody, is generally mild. Infusion-related reactions included rigors, nausea, urticaria, fatigue and headache (Dillman, 2002). One advantage of...

The future role of tumour markers in disease management

Other approaches are being investigated to examine circulating autoantibodies which are raised against the tumour markers themselves. In patients with cancer, these would be expected to be higher than in cancer-'free' individuals. In the case of MUC-1, serial serum samples from primary breast cancer patients showed significant correlation between tissue staining and circulating autoantibodies.

Genetic screening of cancer

So far, the only major familial cancer screened for is familial breast and ovarian cancer caused by the genes BRCA-l and BRCA-2. Some cancer centres now offer screening for BRCA-1 and BRCA-2 mutations in families with multiple cases of these tumours. If mutations are found it is estimated that a woman has up to an 85 lifetime risk of developing breast cancer and a 60 risk of developing ovarian cancer (Armstrong et al., 2000). If BRCA mutations are detected, intensive monitoring can be used to pick up developing tumours at an early stage. For the most high-risk cases preventive measures such as prophylatic mastectomy, or taking drugs that reduce the chances of these cancers (such as tamoxifen), can be considered. Unfortunately BRCA-1 and BRCA-2 mutation-associated familial cases account for only around 15-20 of familial cancers, so possibly there are many genetic risk factors yet to be discovered (Balmain, 2001). Genes that confer strong susceptibility to other familial cancers may...

Effect Of Botanicals On The Breast

The role of food in health and disease is of immense and ongoing interest. One of the most studied botanicals is soy. Soy has been reported to have protective effects against breast cancer in Asian women. At least two studies have evaluated the effect of soy isoflavones on the breast using NAF, one (Hargreaves et al., 1999) short term (2 weeks) and the other (Petrakis et al., 1996) for a longer duration (6 months). The short-term study administered 45 mg soy isoflavones to 84 healthy premenopausal women. They found that the isoflavones genistein and daidzein were concentrated in NAF compared to matched serum, both before and after soy supplementation, and that apolipoprotein D (apoD) levels were significantly lowered and pS2 levels were raised in response to soy ingestion (pS2 levels rise and apoD levels go down in response to estrogen Harding et al., 2000). NAF cytology did not significantly change. In the longer-term study, which evaluated both pre- and postmenopausal white...

Naf As A Tool To Investigate The Presence Of Mutagens In The Breast

It is thought that environmental mutagens stored in the adipose tissue of the breast could affect carcinogenesis through direct exposure to the adjacent ductal epithelial cells, and that evaluating NAF would provide information on carcinogen exposure (Petrakis et al., 1980). A standard assay for the presence of mutagens is the Ames test using one of a variety of Salmonella strains to detect the mutagen. A number of studies using different Salmonella strains have been conducted (Klein et al., 2001 Petrakis et al., 1980 Scott and Miller, 1990). One limitation of the assays performed to date is the need for approximately 10 ml (microliters) of NAF, which is more than is obtained from some subjects. No association was found in the studies between mutagenic activity in NAF and breast cancer.

Surface Enhanced Laser Desorption Ionization Timeof Flight Mass Spectrometry Selditofms

Although 2-D-PAGE is quite powerful, it has limitations in protein separation and sensitivity. Recent advances in comprehensive molecular technologies allow the simultaneous analysis of multiple protein expression targets. The SELDI-TOF technique can be performed with 1 ml of NAF, can detect components in the high femtomole range, and the chip surface, which allows the rapid evaluation of 8 to 24 samples, has high-throughput potential. Candidate breast cancer biomarkers can be identified using mass spectrometric techniques or an immunoassay to the suspected protein can be used to confirm its identity. A wide array of proteins are secreted into and highly concentrated in NAF and have been associated with breast cancer. We are aware of three pilot studies (Coombes et al., 2003 Paweletz et al., 2001 Sauter et al., 2002c) that demonstrate the feasibility of SELDI-TOF analysis of NAF in a limited number of subject samples, and that identified one or more protein mass peaks associated with...

Two Dimensional Polyacrylamide Gel Electrophoresis

Were analyzed using enzyme-linked immunosorbent assay (ELISA), a high-throughput method of evaluating protein concentration. Considering all subjects, GCDFP-15 levels were significantly lower and AAG levels significantly higher in breasts with cancer. This was also true in pre- but not postmenopausal women. GCDFP-15 levels were lowest and AAG levels highest in women with DCIS. Menopausal status influenced GCDFP-15 and AAG more in women without than with breast cancer. ApoD levels did not correlate significantly with breast cancer.

Endogenous Substances Proteomic Analysis

Recent advances in comprehensive molecular technologies have allowed the analysis of global gene expression or protein profiles in cancerous vs. normal tissues with the goal of identifying markers that are differentially expressed between benign and malignant tissue. One such study (Porter et al., 2001) used serial analysis of gene expression to identify molecular alterations involved in breast cancer progression. The authors concluded that many of the highly expressed genes encoded secreted proteins, which in theory would be present in NAF.

Mutations in Mitochondrial DNA

A second report collected matched tumor and benign tissue and NAF from 15 women with breast cancer (Zhu et al., 2005). Fourteen of the 15 (93 ) cancer samples had one or more somatic mtDHA mutations. Four of nineteen mtDNA mutations in the cancer samples were found in matched NAF. No mutations were found in five matched NAF samples from women whose cancers lacked a mutation in the same region.

Nuclear DNA Alterations

Both deletions in DNA, evidenced by loss of heterozygosity (LOH), and changes (either gains or losses) in the number of repeat units of DNA (de la Chapelle, 2003), termed microsatellite instability (MSI), had been identified in a variety of human physiological fluids from subjects with cancer, including sputum (Arvanitis et al., 2003), urine (Neves et al., 2002), stool (Koshiji et al., 2002), blood (Schwarzenbach et al., 2004), and SND (Miyazaki et al., 2000). To determine if LOH and or MSI could be identified in NAF from subjects with breast cancer, DNA from matched NAF and breast tissue samples was extracted and 11 microsatellite markers evaluated (Zhu et al., 2003). An identical LOH MSI alteration was detected in NAF from 33 of proliferative and 43 of cancerous breasts which harbored the change in matched tissue.

Initial Studies Of Naf Focus On Feasibility

The ability to collect NAF was linked not only to age, race, and menopausal status, but also to body habitus. In a large sample of white and black women between the ages of 20 and 59 years old who did not have a history of breast cancer, the proportion of women from whom NAF was collected increased with increasing dietary fat consumption (Lee et al., 1992b). This association of NAF yield with fat consumption was especially strong among black women, and was most pronounced in women aged 30 to 44 years.

Transcript Survey Techniques

The potential of microarrays to address key issues of development and differentiation was immediately realized.30-32 In a single experiment, this technology permits the simultaneous determination of the expression of thousands of genes. This enables the construction of detailed expression and genetic profiles.33-35 Recent microarray-based ovarian and breast cancer studies have demonstrated both the potential diagnostic and prognostic value of this method.36,37 It is also clear that this technology

The impact of research on patient care

10.27 In the future, successful chemotherapy is likely to become increasingly dependent on understanding an individual's genetic background. In partnership with other cancer research funders, we will promote the development of pharmacogenetic studies in the area of cancer chemotherapy.

Cancer Services Collaborative

The Cancer Services Collaborative (CSC) is part of the NHS Modernization Agency. The objective of the CSC teams, which are linked to individual networks, is to look at the provision of specific cancer services within an organization, e.g. breast cancer, and 'map' the patient journey. The results of this mapping exercise identify where the delays are for the patient. Before the publication of The NHS Cancer Plan (DoH, 2000a), nine cancer networks were already taking part in CSC projects. The results from these early projects clearly highlighted that many of the delays in patients' treatment were a result of the way the 'systems' for delivering their care were organized. Through working with all the staff involved, the 'systems' could be redesigned to expedite patients' journeys, e.g. pre-booking patients at the time of referral for diagnostic tests, based on the information contained in their referral letter (DoH, 2000a).

A diagnosis of cancer

As discussed earlier in this book, cancer is a group of diseases, with some forms of malignancy, such as basal cell carcinoma of the skin, carrying an excellent prognosis for the patient (Ketcham and Loescher, 2000). However, the word 'cancer' has been used. As health professionals we must not be complacent when using the word 'cancer'. It is important that the diagnosis is imparted to the patient, and their families and carers, with tact and adequate explanation of its potential implications, even if it is a form of the disease that responds well to treatment (DoH, 2000a Young, 2001). Cancer instils fear in most individuals affected. Many patients, together with their family and friends, experience feelings of uncertainty about their future. Young (2001) discusses how patients want honest and positive answers. Is the disease treatable If so, what will the treatment involve - surgery, radiotherapy, chemotherapy What is the likelihood of the success of the treatment Will the cancer, or...

Relevance Of Peripheral Blood In Assessment Of Patients With Solid Tumors

Of the major tumors afflicting the worldwide population, more progress has been made in applying transcriptional profiling to breast cancer than any other tumor. An initial expression profiling study in breast cancer characterized the differences between breast carcinoma tissue and human mammary epithelial cells,1 while another examined transcriptional profiles in laser dissected normal, malignant, and metastatic breast cancer cell populations from the same patient.2 The latter study identified many differences between normal and malignant profiles, confirming that transcrip-tional patterns of breast tumors would be distinct from transcriptional patterns in nonmalignant tissue. Soon thereafter multiple laboratories extended these results by investigating larger sets of breast tumor profiles and demonstrating correlations Perou et al. showed that unsupervised analysis of breast tumor profiles using 496 informative genes exhibiting large intervariability (high variation across different...

Surrogate Tissue Profiling In Translational Medicine And Oncology Drug Development

Chemotherapeutics are undergoing a revolution in the field of cancer drug development. Whereas previous chemotherapeutic strategies typically included the identification of highly toxic agents designed to kill tumor cells in a nonspecific manner, more and more oncology drug development programs are focusing on agents that target specific molecular features of specific types of tumors. The recent development of Trastuzumab (Herceptin, Genentech, San Francisco, CA) and Imatinib (Gleevec, Novartis, Basel, Switzerland) provide excellent examples of translational strategies implementing predictive biomarkers that identify patients who will most likely respond to specific therapies (for a more in-depth review, see Reference 12). Trastuzumab is a recombinant antibody developed against HER2 based on the role of HER2 in cellular proliferation1314 and its overexpression in breast cancer and association with poor prognosis in this population.1517 HER2 assessment by an immu-nohistochemical assay...

Negative IDFpositive IDF

In the future, the importance of these signs in MRM should be tested in a multicenter study. It would also be prudent to include additional measuring techniques that are not currently in routine use, and to take into account other modalities such as ultrasound, PET, and clinical parameters. The influence of medications, hormones, and chemotherapies should also be considered.

Endogenous Substances Single Protein Analysis 9411 Hormones and Growth Factors

Levels of a number of these factors have been compared to disease risk. With the exception of recent parity, no relation was found between levels of estrogen in NAF and breast cancer risk. Higher levels of estradiol and estrone were found in the NAF of women with benign breast disease than in controls (Ernster et al., 1987). There is a decrease in estradiol and estrone levels in NAF following pregnancy or lactation that persists for several years before returning to prepregnancy levels Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are two of the most important angiogenic factors that stimulate tumor growth (Folkman and Klagsbrun, 1987 Folkman and Shing, 1992). A preliminary report that analyzed 10 patients with breast cancer and 10 controls found that bFGF levels in NAF were higher in women with breast cancer than in normal subjects (Liu et al., 2000). A larger study, which evaluated 143 NAF specimens (Hsiung et al., 2002), also found that mean...


Sign 2 basically describes a slow rate of initial contrast enhancement. This pattern is typically seen in fibrous fibroadenomas, scars, and foci of adenosis. Hormonal effects relating to the normal menstrual cycle may cause a 10 to 20 change in this sign, with less enhancement occurring during the initial phase of the cycle and greater enhancement occurring during the second half of the cycle. The presence of sign 2 in a mass lesion most likely indicates a fibrous fibroadenoma or a scar. The presence of this sign in a non-mass lesion indicates either normal parenchyma, fibrosis, or mild inflammation (mastitis). Very rarely, carcinoma in situ may also display this sign, in which case the enhancement is asymmetrical and unilateral. It should be noted, however, that gradual enhancement may occur in carcinomas as a result of incomplete contrast injection, excessive compression, or chemotherapy in the recent past. It should also be noted that sign 2 depends strongly on the type of contrast...


Targeting growth factor-mediated signaling offers a paradigm for treating cancer. While past efforts focused on the effects of cytotoxic therapies with chemotherapy and radiation therapy, the future looks towards the integration of molecular targeted therapies into current treatment modalities. Given the primarily cytostatic nature of growth factor-targeted biological therapy, its role is likely to be administration in combination with cytotoxic therapy for tumor eradication, and in exploring advantages to administering these agents as maintenance therapy in order to obtain tumor growth inhibition (Thompson et al., 1997). The safety profiles of these biological agents allows for combination therapy with chemotherapy and or radiation therapy, which means that multiple mechanisms of antitumor activity are possible. As early as the 1970s, Judah Folkman theorized that antiangiogenic agents could be used for chronic therapy (Folkman, 1971). It has been theorized that multiple biological...

Sign 120

As a rule, edema associated with a breast lesion is confined strictly to the ipsilateral breast. The patho-biochemical and pathophysiologic changes caused by the tumor affect that breast while sparing the opposite breast. Bilateral edema may occur in association with bilateral breast cancer or in systemic diseases such as heart failure. We have seen cases, however, in which unilateral edema documented before chemotherapy migrated into the opposite breast after the start of chemotherapy. We have not yet found an adequate pathophysiologic explanation for this phenomenon. Tumor breakdown during chemotherapy or the spread of carcinomatous lymphangiosis to the contralateral side has been confirmed in a few isolated cases but has not been found in other cases. A lesion is smaller and no longer enhances after chemotherapy but is still detectable as a mass on T1-weighted precontrast and T2-weighted images. Chemotherapy As a rule, successful chemotherapy leads to a loss of tumor enhancement...


To investigate the function of a breast cancer support group as perceived by the participants. A convenience sample of 15 women diagnosed with breast cancer, all of whom were attending a cancer support group. Nurses should be cognizant of the functions of a breast cancer support group so that this information can be shared with women.

Imatinib mesylate

Another example of translational oncology research is one of the great successes of recent years, and this is the story of imatinib mesylate (Glivec) has dramatically changed the lives of patients with chronic myeloid leukaemia (CML). CML is a disease of the myeloid stem cell characterized by marked splenomegaly and an increase in the production of white cells. The natural course of CML is a chronic phase, as described above, moving into an accelerated or blast crisis that, untreated, leads to death in a matter of weeks. Treatment aims at controlling the white blood cell count with splenectomy and the chemotherapy drugs busulphan, hydroxurea or interferon. These measures can control the disease for a number of years. Bone marrow transplantation provides the only chance of cure, but only 20 of CML patients are eligible for this highly toxic treatment. Since the development and clinical use of imatinib mesylate, treatment approaches have changed. Traditional chemotherapy aimed at...


Preclinical and clinical work is ongoing. Some centres use anti-angiogenesis agents alone and or in combination with chemotherapy. The aim is to inhibit tumour growth, reduce metastases, prolong survival and improve quality of life (Pinedo and Salmon, 2000). However, is it possible to have concurrent use of cytotoxic chemotherapy and anti-angiogenic agents If the blood supply is suppressed, how do the cytotoxic drugs reach the tumour This is a valid concern, but one that has not yet been elucidated. Animal studies of lung cancer by Leicher, cited by Pinedo and Salmon (2000), demonstrated a synergistic effect. Combination therapy reduced not only the number of metastases but also the size of the metastases, providing evidence that anti-angiogenic therapies can improve treatment.


Given the effects of growth factors on processes such as proliferation, differentiation, survival, apoptosis, angiogenesis, invasion, and metastasis, it is clear that aberrant growth factor signaling is a major factor in malignant transformation. Targeting growth factors at the molecular level and disrupting aberrant signaling pathways presents a rational and unique approach to anticancer treatment, particularly for cancers for which only limited treatment options are available. Traditional chemotherapeutic and radiation approaches used for late-stage cancers typically provide modest benefit, often limited to short-term palliation. In addition to the efficacy limitations associated with chemotherapy and radiation, their toxicity profiles often limit administration at the dose and or schedule necessary for tumor eradication. The field of molecular targeting of various aspects of the growth factor signaling pathways has grown tremendously over the past few decades, and promising...

Breast Carcinoma

The majority of patients with mammary carcinoma (approximately 90 ) present with tumors that are clinically confined to the breast and neighboring axillary lymph nodes. Essentially, all these patients are rendered free of measurable disease after primary surgery.73 Despite this highly efficient locoregional therapy, 30 to 40 of these patients will develop clinically detectable metastases within 10 years if no further treatment is instituted.73 The chief reason for these relapses is that breast carcinoma cells disseminate throughout the body early in tumor development.74 To prevent the clinical progression of these micrometastases, about two thirds of the patients diagnosed with stage I to III breast cancer are candidates for adjuvant or neoadjuvant chemother-apy.75 It has been reported that approximately 36 of these women would remain free of disease using locoregional therapy alone. Routine adjuvant chemotherapy would subject these patients to unnecessary and toxic treatment. To...

Tumor Antigens

A number of proteins present in NAF have previously been associated with cancer in the blood. Two of these are PSA and carcinoembryonic antigen (CEA). PSA, a chymotrypsin-like protease first found in seminal fluid and associated with prostate cancer (Soderdahl and Hernandez, 2002), is also found in breast tissue (Howarth et al., 1997 Sauter et al., 2002b) and in NAF. PSA levels in cancerous breast tissue are lower than in benign breast tissue (Sauter et al., 2002b). PSA is thought to cleave insulin-like growth factor binding protein-3 (IGFBP-3), the major binding protein of IGF-I. Most (Sauter et al., 1996, 2002a, 2002b) but not all (Zhao et al., 2001) studies indicate that low NAF PSA levels are associated with the presence and progression (Sauter et al., 2004b) of breast cancer, whereas high levels of NAF IGFBP-3 have been linked to breast cancer (Sauter et al., 2002a). One explanation for the discrepancy in PSA results may be the difference in NAF yield, which was 97 of subjects in...

Image Analysis

While NAF cytologic evaluation is very specific in the diagnosis of breast cancer, it is not very sensitive (Krishnamurthy et al., 2003 Papanicolaou et al., 1958 Sauter et al., 1997). One approach that has been used to increase the sensitivity of NAF is to evaluate the DNA content of the cells. Normal cells contain 46 chromosomes, are called diploid, and have a DNA index (DI) of 1.0. An abnormal amount of cellular DNA is called aneuploidy and is associated with a high nuclear grade. Hypertetraploidy is used to describe a cell that contains more than twice the normal DNA content, and has a DI > 2.0. cytology and is associated with the presence of breast cancer (Sauter et al., 1997). Abnormal DNA ploidy is highly predictive of the presence of residual breast cancer after diagnostic biopsy (Sauter et al., 1999).


Significant advances have been made in the molecular genetic research of breast cancer in recent years, and striking differences have been noted among different types of carcinoma. Genomics, microchips, and proteomics are buzzwords for new discoveries suggesting that, in the future, we will be able to analyze molecular subgroups in order to obtain specific information about an individual cancer. More than 600 genes are over- or underregulated in a tumor. A carcinoma is like a new life in a living patient. This genetic information determines the aggressiveness of the tumor, the likelihood of metastasis, and the organs to which the tumor will metastasize (bone, liver, brain, lung, etc.), thus critically influencing the prognosis. Breast cancers are not all the same. They are a

Data Interpretation

Perhaps the greatest challenge of all will be the interpretation and appropriate utilization of all the omic and other data obtained from target and surrogate tissues. Validating the relationship between gene expression or protein profiles and toxicant exposure or disease state has already begun. If and when these relationships have been fully verified in target tissues, then the relationship between gene or protein expression in target and surrogate tissues must be established. In doing so, it will be necessary to determine whether genetic or proteomic biomarkers of toxicity or disease in target tissues are reflected in the surrogate tissue across a range of doses, time points, and disease states. Alternatively, omic biomarkers in surrogate tissues may be of high clinical value but fail to share identity with markers in the primary tissue. For example, one such scenario might involve the transcriptional response of circulating peripheral blood leukocytes due to tumor regression...

General Information

During the period from 1985 to 2006, many authors repeated the almost mantra-like claim that MR mammography has high sensitivity but low specificity. But it is quite possible - and by that I mean very probable - that by utilizing all the information contained in MR data sets, we can greatly increase the specificity of MRM. This would give MRM a very high overall accuracy in the diagnosis and differential diagnosis of breast lesions, making it possible to detect cancers as small as 3 mm with a high degree of confidence. Based on all available scientific information, it is even reasonable to expect that the use of MRM can significantly reduce mortality rates from breast cancer while also reducing the extent of surgical procedures and the use of costly chemotherapeutic agents. If the quality of the diagnostic information can be increased, this will also justify the higher costs of MRM compared with x-ray mammography and breast ultrasound.

Isbn 0792337271

Gradishar, W.J., Wood, W.C. (eds) Advances in Breast Cancer Management. 2000. ISBN 0-7923-7890-3 Bashey, A., Ball, E.D. (eds) Non-Myeloablative Allogeneic Transplantation. 2002. ISBN 0-7923-7646-3 Leong, Stanley P.L. (ed) Atlas of Selective Sentinel Lymphadenectomy for Melanoma, Breast Cancer and Colon Cancer. 2002. ISBN 1-4020-7013-6 Andersson, B., Murray D. (eds) Clinically Relevant Resistance in Cancer Chemotherapy. 2002. ISBN 1-4020-7200-7.

Rays Ultrasounds and Other Diagnostic Pictures

X-rays of all of the major bones in the body, called a metastatic survey, are very useful to look for thyroid cancer metastasized to bones. Metastatic surveys are particularly helpful if the thyroglobulin is very elevated and the radioactive iodine whole body scans fail to show the site of the cancer. In other types of cancer, such as breast cancer or prostate cancer, nuclear bone scans are used for this purpose. In thyroid cancer, nuclear bone scans are insensitive and usually useless in showing such disease in bones.

Hypofractionation for Prostate Tumors

Individual measurements of the repopulation would be a major advance, and further determinations of Tk are still needed, as explained above. Perhaps some kinds of chemotherapy work by slowing down repopulation, making the shorter, hotter, schedules unnecessary as a biological advantage, although they could still be useful for resource economy and for limiting total dose and hence late injury.

Clinical Presentations

Acute effects from CNS-directed therapy are relatively uncommon. Acute radiation changes to the CNS can result in significant edema at the irradiated site (often following single dose therapies such as gamma knife or stereotactic radiosurgery) and may present with worsening of pre-existing symptoms (i.e. seizure, weakness, headaches). These symptoms, when they occur, are usually manageable with corticosteroid therapy 56 . Acute effects of chemotherapy on the CNS are also relatively uncommon. Ifosfamide has been associated with changes in mental status, cerebellar function, cranial nerve function, and cere-bellar and motor system function, as well as with seizures 57 . The risk of this acute toxicity may be exacerbated by prior chemotherapy exposure, specifically exposure to cis-platinum 58 . Ara G, a new antimetabolite with selective efficacy against T-cell leukemia, is also associated with acute neurotoxicity. Somnolence and other acute CNS changes may be dose-limiting for this new...

Clinical Correlations

There are many ways in which mutations in cancer-promoting genes can occur. The predisposition to cancer can be inherited, as in patients with Li-Fraumeni syndrome, whose cells contain a germ-line mutation ofp53, one of the cell cycle checkpoint regulators described above. Cells from patients with chronic myelogenous leukaemia often contain an abnormal chromosome resulting from a translocation between chromosomes 9 and 22, the so-called Philadelphia chromosome (Rowley, 1973). This abnormal fusion juxtaposes two genes, which code for the proteins BCR and the Abl tyrosine kinase, and results in aberrant activity and subcellular localization of the Abl protein. In breast cancer, BRCA1 is mutated at specific sites in the gene. Such mutations are largely inherited. et al., 1999). In women, reproductive history and the resulting cumulative lifetime exposure to oestrogen correlate with an increased risk of breast cancer (Hankinson et al., 1995). How environmental factors trigger the...

Experiments in Medicinal Uses of Saffron

Folklore relating to the uses of saffron treats its effect on blood clots (Szita 1987). Research at the Institute for Oriental Medicine in Hyogo has shown that saffron stigmas inhibit blood coagulation, via their effect on platelet-aggregation, and accelerate in vitro fibrinolysis activity of urokinase and plasmin (Nishio et al. 1987, 1993). The toxicity of saffron extract, known from ancient times (Basker and Negbi 1983), has recently been studied in rabbits and dogs (Babaev et al. 1990). Possibly related is the effect of saffron's ethanol extract on learning ability in mice (Zhang et al. 1994). Saffron chemotherapy has recently been reviewed by Nair et al. (1996). Recent progress relating to saffron in biological and medical research is discussed by Abdullaev and Frenkel (this volume).

Injury of the Hypothalamic Pituitary Axis in Patients with Cancer

The hypothalamic-pituitary axis (HPA) is vulnerable to damage by certain tumors, surgical trauma, irradiation, and chemotherapy 11, 60 . A summary of common risk factors for HPA disorders that develop after cancer treatment is presented in Table 5.2. Patients with tumors in the area of the HPA (e.g. craniopharyngioma or hypothalamic chiasmatic tumor) are at particular risk for neuroendocrinopathy 15, 33 . Many HPA injuries are attributable to damage caused by radiation therapy (see section However, the incidence of pre-RT neuroendocrino-pathies in pediatric patients with brain tumors is high. For example, out of 68 pediatric patients in one study 32 , 45 (66 ) showed evidence of neuro-endocrinopathy before RT,including 15 of 32 patients with tumors in the posterior fossa not adjacent to the HPA. Seventeen of the 45 patients (38 ) revealed abnormalities in GH, 19 (43 ) in TSH and 10 (22 ) in ACTH. Six patients (13 ) had aberrations in gonadotropin. In addition to these...

Clinical Manifestations 521 GH Deficiency

Prospective study, all of the 21 children treated with a total dose of more than 45 Gy for optic pathway tumor experienced GH deficiency and a significant slowing of growth within 2 years after irradiation 6 . At doses of cranial irradiation higher than 30 Gy (e.g. for suprasellar or posterior fossa tumor), the risk for GH deficiency may be more than 80 by 10 years after RT 59 . Cranial irradiation doses greater than 24 Gy result in GH deficiency in as many as two thirds of patients who receive this treatment 60, 62 . In many younger children, GH deficiency results from lower doses (> 18 Gy). Doses of only 12-14 Gy, when used for total body irradiation, combined with chemotherapy and bone marrow transplantation, also pose a significant risk for GH deficiency 24, 26,62 .

LiFraumeni Syndrome LFS

This cancer predisposition syndrome was first outlined in 1969 by Li and Fraumeni (1969). They reported four families with autosomal dominant predisposition to soft tissue sarcoma, breast cancer and other tumours in children and adults. Many reports have followed, either describing further families or reporting an increased risk of cancers in first degree relatives of cases with soft tissue sarcoma. In 1988, Li et al. (1988) analysed 24 kindreds with an aggregation of tumours typical of the syndrome. They showed a predominance of soft tissue sarcoma, osteo-sarcoma and breast cancer, with an excess of adrenocor-tical carcinoma, brain tumours and leukaemia. Williams and Strong (1985) applied a segregation analysis to test the hypothesis that the disease was due to an autosomal dominant gene. They not only confirmed this, but also were able to predict that 50 of gene carriers would develop an invasive cancer by 30 years of age and 90 by 70 years. Although the syndrome (also known as...

Massive Malignant Infiltration of the Liver

Massive infiltration of the liver with either metastatic adenocarcinoma1 or lymphoma can result in FHF or SFHF.132-135 Mechanisms of liver failure include ischemia from sinusoidal invasion of the tumor cells and cytokine release.133,136 In some cases of lymphoma, early chemotherapy can result in increased patient survival. Metastatic disease to the liver, lymphoma and primary hepatic tumors such as angiosarcoma and hemangioendothelioma are absolute contraindications for liver transplantation.137,138

Common Mechanisms of Taxanes and Platinum Drug Resistance

As discussed previously, both classes of antineoplastic agents commonly used in chemotherapy of ovarian cancer, taxanes and platinum drugs, in the end induce cellular pathways leading to apop-tosis. Consequently, inhibition of pro-apoptotic pathways and activation of anti-apoptotic pathways can lead to drug resistance in ovarian carcinoma. Various in vitro models demonstrate that a critical balance exists between cell cycle arrest allowing DNA repair and drug resistance, and triggering of apoptosis and thereby sensitivity against drug treatment. In the tumour cells, an intricate network of factors and pathways has evolved to control this balance. Response to chemotherapy may also be affected through enhanced synthesis of additional anti-apoptotic factors, or the reduced activity of pro-apoptotic proteins. An important role for the clinical outcome of ovarian carcinoma following chemotherapy has also been associated with various other apoptosis-regulating genes including Bcl-2 (Mano et...

Specific Chemotherapeutic Agents

Agents, including ionizing radiation, and expression of the receptor in a cancer is often associated with an aggressive neoplasm that is resistant to chemotherapy (Mendelsohn and Fan 1997 SchmidtUllrich et al. 2000). The formation of blood vessels necessary for tumor growth is dependent on angiogenic factors such as VEGF, and inhibitors have been shown to improve the efficacy of irradiation (Teicher et al. 1995 Mauceri et al. 1998).

Acquired Thrombophilias

Other alleged causes of acquired thrombophilia include paroxysmal nocturnal haemoglobinuria, nephrotic syndrome, various myeloproliferative disorders, and malignancies and cancer chemotherapy (not necessarily involving inhibitors of folate metabolism). The mechanisms are generally obscure.

Multimodality Therapeutic Strategies That Include Surgery

Preoperative Chemotherapy Cisplatin-based combination chemotherapy has been evaluated in numerous phase II trials as induction or neoadjuvant therapy prior to esophagectomy. Because of the frequency of distant metastatic disease, the addition of a systemic therapy is logical. Approximately 50 of patients demonstrate at least a 50 reduction in tumor mass after two or three courses of cisplatin and infusional 5-fluorouracil (5-FU), a well-established regimen in the treatment of this disease. Occasional patients (< 5 ) have no evidence of tumor in the resection specimen.

Wnt Signaling in Cancer

Deregulation of the Wnt signaling pathway can be found in many different human cancers. Changes in expression levels have been described for many components of the Wnt pathway. Overexpression of Wnt factors has been reported in several primary human malignancies including gastric cancer, head and neck squamous cell carcinoma, colon carcinoma, and chronic lym-phocytic leukemia (85-88). Several frizzled receptors have been found to be upregulated in esophageal, gastric, and colon cancers as well as in head and neck squamous cell carcinomas (86,87,89,90). The Wnt coreceptor LRP-5 has recently been reported to be overexpressed in osteosarcoma (91). Overexpression of dishevelled has been found in primary breast cancer, cervical squamous cell carcinoma, and mesothelioma (92-94). Also Frat1, which

Targeting the Initiation of Wnt Signaling at the Cell Membrane

Activation of canonical Wnt signaling involves binding of Wnt ligands to frizzled receptors and LRP-5 6 co-receptors. This can be antagonized by the endogenous inhibitors of Wnt signaling sFRPs, WIF-1, and Dkk. Overexpression of Dkk-3 has been demonstrated to inhibit growth of lung cancer cells and invasion and motility of osteosarcoma cells (152,153). The expression of Dkk-1, which is a transcriptional target of p53, has been shown to be induced upon treatment of cancer cells with chemotherapeutic agents, and re-expression of Dkk-1 in cells lacking endogenous Dkk-1 sensitized these to chemotherapy (154). These data suggest a potential of Dkk proteins as adjuvants for chemotherapy.

The Need For Dna Repair

Increase in 8-oxoG, 8-hydroxyadenine and in DNA in breast cancer tissue compared with normal tissue has been reported (Wiseman and Halliwell, 1996). DNA damage can also occur after direct attack by external or exogenous sources. Radiation from various sources can directly damage bases in DNA. For example, ultraviolet (UV) irradiation from exposure to sunlight creates certain DNA lesions. The main ones are the cyclobutane pyrimidine dimers formed usually between two adjacent thymine bases in DNA and the pyrimidine--6,4--pyrimidine dimer photoproducts. Irradiation from 7-ray sources or X-rays creates many different kinds of lesions in DNA, including base modifications, sites with a loss of base, and breaks in a DNA strand. DNA breaks can be single- or double-stranded. Many food constituents can directly damage DNA. These include carcinogens or chemicals that react directly with DNA or do so after metabolic modification. Some of these agents alkylate DNA bases, some forming bulky...

Infertility secondary to cancer and cytotoxic treatments

Childhood cancer is rare - the risk for an individual child developing cancer in the United Kingdom before the age of 15 years is 1 in 500. Seventy-three per cent of patients are still alive five years after diagnosis (Toms 2004). Both radiotherapy and chemotherapy may directly damage the ovary or testis, while tumours and radiation to the brain may affect the hypothalamo-pituitary axis (see above). The extent of resulting infertility is unclear as Currently it is thought that 15 per cent of survivors will have a high risk of early and irreversible gonadal failure, while others may have a lower risk of compromised reproductive capacity (Wallace etal. 2001). Males appear to be more susceptible to sub-fertility following chemotherapy than females, while some females may be at risk of premature menopause.

Stem Cells In Leukemia

LEUKEMIC SPLEEN COLONIES AND A CELLULAR BASIS FOR CHEMOTHERAPY An experimental link was made between normal stem cells and their leukemic counterparts when Bruce and colleagues showed that murine leukemia cells could form colonies in the spleens of genetically identical recipients (Bruce and van der Gass, 1963). These colonies were found to contain cells that were easily shown to be very similar to the leu-kemic cells from which they were derived. Bruce used his method to measure dose-response curves for radiation and drugs used in cancer treatment. The discovery that was to have the greatest impact was made when both normal and leukemic spleen colony assays were used to study very rare stem cells that could not be detected by any other means. The question was, could CFUs exist in a resting state For common cell populations, radioautography, using tritiated thymidine (3HTdR), allowed cells in DNA synthesis to be recognized and, using kinetic procedures, other components of the...

Search For Association Between Blast Properties And Outcome

Growth factors might prove useful in treatment if combined with chemotherapy the idea was that administration of factor might increase the number of cells in the S phase of the cycle and hence their sensitivity to cycle-dependent drugs. Further, growth factors might reduce the time in aplasia following drug treatment and thus decrease the number of early deaths from infection or bleeding. Many trials were done and conflicting results obtained (summarized in Buchner et al., 1998) a consensus is emerging that adding growth factors to treatment protocols does not significantly improve treatment outcome. The major clinical use of growth factors is to mobilize stem cells from marrow to peripheral blood, where they may be collected with ease for supportive care or transplantation (Sheridan et al., 1992). they were never strong enough to be used to predict drug response or select chemotherapy (Dow et al., 1986 Griffin and Lowenberg, 1986 Nara et al., 1986 McCulloch, 1990). drug sensitivity,...

Clinical Presentation

Figure 7-18 Infiltrating spindle cell sarcoma with myxoid stroma, involving the lower trachea (T), carina, and much of the left main bronchus (Lt), in a 28-year-old man. Carinal resection and left pneumonectomy were followed by 6,000 cGy irradiation and chemotherapy. The hook in the gross specimen is at the carina. The patient died 3 years later of tumor progression. figure 7-18 Infiltrating spindle cell sarcoma with myxoid stroma, involving the lower trachea (T), carina, and much of the left main bronchus (Lt), in a 28-year-old man. Carinal resection and left pneumonectomy were followed by 6,000 cGy irradiation and chemotherapy. The hook in the gross specimen is at the carina. The patient died 3 years later of tumor progression.

Official Download Page Chemo Secrets From a Breast Cancer Survivor

Chemo Secrets From a Breast Cancer Survivor will be instantly available for you to download right after your purchase. No shipping fees, no delays, no waiting to get started.

Download Now